Norway's Hofseth Biocare Q1 revenue falls on production disruption

Hofseth Biocare ASA

30/06/2026 11:24

Overview
Norway consumer and pet health firm's Q1 revenue fell yr/yr due to plant maintenance
Gross margin rose as portfolio shifted toward bioactive, clinically differentiated ingredients
Company completed private placement after Q1, restoring equity and liquidity position

Outlook
Company expects Q2 2026 revenue to be comparable to Q2 last year despite lower production
HBC expects to return to full production by end of Q3 2026
Several new OmeGo product launches planned for Q3 with leading global brands

Result Drivers
PRODUCTION DISRUPTION - Scheduled maintenance and overhaul at the Midsund plant reduced production volumes and delayed shipments, impacting Q1 revenue
B2C PROFITABILITY IMPROVEMENT - Consumer & Pet Health segment gross margin improved, supported by Amazon channel clean-up and better supply reliability

Company press release: ID:nGNE1Z7j8V

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
 
NOK 49.50 mln
 
Q1 EBIT
 
-NOK 33.60 mln
 
Q1 EBITDA
 
-NOK 23.20 mln

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)